<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Decreased cerebral blood flow causes <z:hpo ids='HP_0100543'>cognitive impairments</z:hpo> and neuronal injury in the progressive age-related <z:e sem="disease" ids="C0524851" disease_type="Disease or Syndrome" abbrv="">neurodegenerative disorders</z:e> such as <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> (AD) and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, we for the first time found that nobiletin, a novel leading compound for AD therapy, improved <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>-induced <z:e sem="disease" ids="C0233794" disease_type="Mental or Behavioral Dysfunction" abbrv="">memory deficits</z:e> in vivo </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment with 50 mg/kg of nobiletin (i.p.) for the consecutive 7 days before and after <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> significantly inhibited delayed neuronal <z:hpo ids='HP_0011420'>death</z:hpo> in the hippocampal CA1 neurons in a 20-min bilateral common carotid <z:mp ids='MP_0006134'>arteries occlusion</z:mp> (BCCAO) <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>However, the contextual memory assessed by passive avoidance task was not improved </plain></SENT>
<SENT sid="4" pm="."><plain>On the other hand, a 5-min BCCAO-induced contextual <z:e sem="disease" ids="C0233794" disease_type="Mental or Behavioral Dysfunction" abbrv="">memory deficit</z:e> was significantly improved by the nobiletin treatment </plain></SENT>
<SENT sid="5" pm="."><plain>In the 5-min BCCAO mice, Western blot analysis evidently showed that the levels of synaptic proteins, including calcium/calmodulin-dependent protein kinase II (CaMKII), microtubule-associated protein 2 (MAP2) and <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> receptor 1 (GluR1), significantly decreased in the hippocampal CA1 region </plain></SENT>
<SENT sid="6" pm="."><plain>The nobiletin treatment prevented the reduction in CaMKII, MAP2 and GluR1 protein levels in the hippocampal CA1 region, accompanied by restoration of both ERK and CREB phosphorylation and CaMKII autophosphorylation </plain></SENT>
<SENT sid="7" pm="."><plain>Consistent with the restored CaMKII and ERK phosphorylation, an electrophysiological study showed that the impaired hippocampal long-term potentiation (LTP) observed in the 5-min ischemic mice was significantly improved by the nobiletin treatment </plain></SENT>
<SENT sid="8" pm="."><plain>These findings suggest that the activation of CaMKII and ERK signaling in part mediates improvement of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced learning and <z:e sem="disease" ids="C0233794" disease_type="Mental or Behavioral Dysfunction" abbrv="">memory deficits</z:e> by nobiletin </plain></SENT>
</text></document>